Titlebook: Haploidentical Transplantation; Concepts & Clinical Stefan O. Ciurea,Rupert Handgretinger Book 2018 Springer International Publishing AG,

Diverticulum

書目名稱Haploidentical Transplantation影響因子(影響力)




書目名稱Haploidentical Transplantation影響因子(影響力)學(xué)科排名




書目名稱Haploidentical Transplantation網(wǎng)絡(luò)公開度




書目名稱Haploidentical Transplantation網(wǎng)絡(luò)公開度學(xué)科排名




書目名稱Haploidentical Transplantation被引頻次




書目名稱Haploidentical Transplantation被引頻次學(xué)科排名




書目名稱Haploidentical Transplantation年度引用




書目名稱Haploidentical Transplantation年度引用學(xué)科排名




書目名稱Haploidentical Transplantation讀者反饋




書目名稱Haploidentical Transplantation讀者反饋學(xué)科排名

全神貫注于

Historical Perspective and Current Trends in Haploidentical Transplantation,f the patient needs donor-derived cellular therapies, they are easily accessed. Pioneering studies by Reisner and coworkers showed that full-donor engraftment without graft-.-host disease was achieved by escalating doses of CD34. cells in T-cell-depleted bone marrow in mouse models for T-cell-mediat

crockery

Toward Safer CD34+ Megadose T-Cell-Depleted Transplants Following Reduced Intensity and Nonmyeloablask of higher rates of graft rejection. Thus new approaches to address this challenge are being developed. If successful, non-myeloablative haplo-HCT potentially could offer a highly attractive and safer treatment modality for patients with different hematological diseases or a platform for organ tra

愉快嗎

熟練

Haploidentical Transplantation Using Unmanipulated G-CSF-Primed Blood and Marrow as Allografts: Clin of studies demonstrated that unmanipulated G-CSF-stimulated haploidentical grafts can lead to rapid immune recovery, desirable health-related quality of life (QoL), and a survival rate comparable to that following HLA-matched sibling donor hematopoietic cell transplant (MSD-HCT) or HLA-matched unre

compassion

戲法

Post-transplant Cyclophosphamide in Haploidentical Transplantationl transplantation utilizing post-transplant cyclophosphamide achieves comparable survival to HLA-matched transplantation and has thereby expanded the option of allogeneic transplantation to the vast majority of eligble recipients.

Intrepid

共同時代

Haploidentical Transplants and NK Cell Alloreactivityyeloid leukemia. Under T-cell-replete protocols, the benefits of NK cell alloreactivity might be expected to be antagonized/obscured as was reported in unrelated donor and cord blood transplantation. The only exception so far documented is the haploidentical hematopoietic cell transplant trial with

PET-scan